Figure 7: Cooperation of IL-10 suppression and immune checkpoint blockade.
Created with BioRender.com. Model shows combining IL-10 suppression with anti-PD-L1 ICB enhances antitumor CD8+ T-cell activity by counteracting multiple methods of CLL immune suppression.